ID   PC-3 [Human lung carcinoma]
AC   CVCL_S982
SY   PC-3; PC3; JPC-3; PC3JPC3
DR   CLO; CLO_0037036
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471064
DR   cancercelllines; CVCL_S982
DR   Cell_Model_Passport; SIDM00361
DR   Cosmic; 801572
DR   Cosmic; 844833
DR   Cosmic; 876135
DR   Cosmic; 917973
DR   Cosmic; 929150
DR   Cosmic; 932923
DR   Cosmic; 946056
DR   Cosmic; 1154599
DR   Cosmic; 1239894
DR   Cosmic; 1571734
DR   Cosmic; 1995465
DR   Cosmic; 2125283
DR   Cosmic; 2668305
DR   Cosmic-CLP; 1240202
DR   DepMap; ACH-002184
DR   EGA; EGAS00001000978
DR   GDSC; 1240202
DR   GEO; GSM827580
DR   GEO; GSM1670340
DR   IARC_TP53; 2384
DR   JCRB; JCRB0077
DR   LINCS_LDP; LCL-1664
DR   PharmacoDB; PC3_JPC3_1249_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_S982
DR   Wikidata; Q54938404
RX   PubMed=1847845;
RX   PubMed=8286010;
RX   PubMed=9290701;
RX   PubMed=10358721;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=15999539;
RX   PubMed=16105816;
RX   PubMed=19472407;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.
CC   Population: Japanese.
CC   Doubling time: 41.7 hours (PubMed=8286010); ~90 hours (Note=Lot 01072008), ~45 hours (Note=Lot 09302011), 2-4 days (Note=Lot 07162019) (JCRB=JCRB0077).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Ala750delinsPro (c.2239_2248delinsC) (c.2239_2248TTAAGAGAAG>C); ClinVar=VCV000177684; Zygosity=Unspecified (PubMed=16105816).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.27%; Native American=0%; East Asian, North=77.82%; East Asian, South=20.28%; South Asian=0%; European, North=0%; European, South=1.63% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): Cosmic-CLP=1240202; JCRB=JCRB0077
ST   Amelogenin: X
ST   CSF1PO: 12,15
ST   D13S317: 11,12
ST   D16S539: 10
ST   D5S818: 12
ST   D7S820: 11,13
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 02-05-24; Version: 30
//
RX   PubMed=1847845; DOI=10.1007/BF00685110;
RA   Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T.,
RA   Saijo N.;
RT   "Prediction of the antitumor activity of new platinum analogs based on
RT   their ex vivo pharmacodynamics as determined by bioassay.";
RL   Cancer Chemother. Pharmacol. 27:263-270(1991).
//
RX   PubMed=8286010;
RA   Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.;
RT   "Inhibitory effects of cholera toxin on in vitro growth of human lung
RT   cancer cell lines.";
RL   Anticancer Drug Des. 8:417-428(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=15999539;
RA   Matsumura T., Takigawa N., Kiura K., Shibayama T., Chikamori M.,
RA   Tabata M., Ueoka H., Tanimoto M.;
RT   "Determinants of cisplatin and irinotecan activities in human lung
RT   adenocarcinoma cells: evidence of cisplatin accumulation and
RT   topoisomerase I activity.";
RL   In Vivo 19:717-721(2005).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//